MPNs

In an interview with Targeted Oncology™, Richard T. Silver, MD, discussed the role of interferon in the treatment of myeloproliferative neoplasm as well as the importance of the 3-year global MPN initiative being conducted by the MPN Research Foundation.

The study is currently recruiting in 5 states and aims to determine if ruxolitinib affects GvHD rates in patients received HSCT for the treatment of myelofibrosis.

Ropeginterferon alfa-2b-njft has been granted FDA approval for the treatment of adults patients with polycythemia vera.

In an interview with Targeted Oncology, Gabriela Hobbs, MD discussed the current treatment landscape for MPNs and the research that is aiming to address post-MPN acute leukemia and unmet needs for the patient population.

During the NCCN 2021 Congress: Hematologic Malignancies, Aaron T. Gerds, MD, MS, explained the risk stratification tools used in patients with myeloproliferative neoplasms.

Srdan Verstovsek, MD, PhD, a professor of Medicine and a hematologic oncologist at the University of Texas MD Anderson Cancer Center, discusses the need for new drugs after patients with myelofibrosis are treated with JAK inhibitors.

A phase 2 study suggests that tipifarnib may be more beneficial for patients with CMML, MDS, or MPNs and RAS pathway mutations than the general population of patients with these disease.

Haris Ali, MD, discussed a 68-year-old woman who presented to her physician with symptoms of fatigue and abdominal pain lasting 4 months; she also reported increased bruising.

Srdan Verstovsek, MD, PhD, a professor of Medicine and a hematologic oncologist at the University of Texas MD Anderson Cancer Center, discusses unmet clinical needs in myelofibrosis.

Add-on parsaclisib showed improvement in spleen volume and symptoms in patients with myelofibrosis who were having a suboptimal response to a stable dose of ruxolitinib.

Srdan Verstovsek, MD, PhD, discussed the future of myelofibrosis treatment, unmet clinical needs in this patient population, and new therapy options in an interview with Targeted Oncology™.

In an interview with Targeted Oncology™ during the SOHO Annual Meeting, Carole Miller, MD, discussed results from the REVEAL study and how the findings can be used to aid future research.

Despite the several classes of drugs either approved, or in development, for the treatment of myeloproliferative neoplasms, a big question remains.

Olatoyosi Sobulo Odenike, MD, explored the risk factors for evolution to MPN AP/blast phase, outcomes for current treatment methods, and potential targeted therapies during a presentation.

The JAK1/JAK2 inhibitor Ruxolitinib has numerous clinical uses for the treatment of polycythemia vera, especially for adult patients who have had an inadequate response to hydroxyurea.

In the REVEAL study, having high-risk polycythemia vera was associated with lower survival at 4 years compared with low-risk disease.

Active phase 2 and 3 studies offer different concepts to the treatment myelofibrosis, according to Srdan Verstovsek, MD.

Adapting therapy to patients using the available criteria may be the key to future treatment in patients with polycythemia vera.

Haris Ali, MD, a hematology oncologist at the City of Hope Comprehensive Cancer Center, discusses common myeloproliferative neoplasms driver mutations. 

Above-average rates of polycythemia vera have been reported for over a decade due to causes unknown to experts. Intriguing new developments in the ongoing research of the genetic, toxicological, and environmental factors related to these cases have created reason to believe that this issue is not a thing of the past.

Haris Ali, MD, discussed the diagnosis and treatment of myelofibrosis with a group of physicians during a Targeted OncologyTCase-Based Roundtable event.

During a Targeted Oncology Case-Based Roundtable event, Andrew Kuykendall, MD, discussed the case of 68-year-old patients with myelofibrosis.

During a Targeted Oncology Case-Based Roundtable, Ruben Mesa, MD, discussed the prognostic risk systems in myelofibrosis.

Selinexor has been administered in combination with ruxolitinib to the first patient with treatment-naïve myelofibrosis as part of a phase 1/2 clinical trial.

Haris Ali, MD, discusses the use of ruxolitinib as peri-transplant treatment for patients with myelofibrosis.

The hepcidin mimetic rusfertide is suggested to reduce the need for phlebotomy in patients with polycythemia vera, according to the results of the phase 2 PTG-300-04 trial presented during the European Hematology Association 2021 Virtual Congress.

Jan Philipp Bewersdorf, MD, discusses the safety outcomes of a systematic review and meta-analysis of 43 studies investigating efficacy and safety of allogeneic hematopoietic cell transplant in 8739 patients with primary or secondary myelofibrosis.

A proportion of patients with myeloproliferative neoplasms were not prescribed medications needed for the management of comorbidities in the United Kingdom, a poster presented during the 2021 European Hematology Association Virtual Congress showed.

Subgroup analyses from the the phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials show that achievement of transfusion independence by the 24th week of treatment is associated with an improvement in overall survival compared with continued transfusion dependence at that time point.

Based on a systematic review and meta-analysis , investigators say allogeneic hematopoietic cell transplant should be considered a standard of care option for patients with high-risk myelofibrosi.